This is a randomized, placebo-controlled, double-blinded, parallel group, multicenter study to evaluate the safety and efficacy of nemolizumab over a 12-week treatment period in patients suffering from prurigo nodularis compared to its placebo.
The aim of this study is to assess the safety and efficacy of nemolizumab in subjects with prurigo nodularis.